The Genetic Architecture of Coronary Artery Disease: Current Knowledge and Future Opportunities

Jaana Hartiala, PhD[1,2,3], **William S. Schwartzman, BS**[1,2,3], **Julian Gabbay, MS**[1,2,3], **Anatole Ghazalpour, PhD**[4], **Brian J. Bennett, PhD**[5,6], and **Hooman Allayee, PhD**[1,2,3]

[1]Department of Preventive Medicine, University of Southern California, Los Angeles, CA 90033

[2]Department of Biochemistry and Molecular Medicine, University of Southern California, Los Angeles, CA 90033

[3]Institute for Genetic Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033

[4]Department of Human Genetics, David Geffen School of Medicine of UCLA, Los Angeles, CA 90095

[5]USDA Western Human Nutrition Research Center, University of California Davis, Davis, CA 95616

[6]Department of Nutrition, University of California Davis, Davis, CA 95616

Abstract

Purpose of review—We provide an overview of our current understanding of the genetic architecture of coronary artery disease (CAD)and discuss areas of research that provide excellent opportunities for further exploration.

Recent findings—Large-scale studies in human populations, coupled with rapid advances in genetic technologies over the last decade, have clearly established the association of common genetic variation with risk of CAD. However, the effect sizes of the susceptibility alleles are for the most part modest and collectively explain only a small fraction of the overall heritability. By comparison, evidence that rare variants make a substantial contribution to risk of CAD has been somewhat disappointing thus far, suggesting that other biological mechanisms have yet to be discovered. Emerging data suggests that novel pathways involved in the development of CAD can be identified through complementary and integrative systems genetics strategies in mice or humans. There is also convincing evidence that gut bacteria play a previously unrecognized role in the development of CAD, particularly through metabolism of certain dietary nutrients that lead to proatherogenic metabolites in the circulation.

Summary—A major effort is now underway to functionally understand the newly discovered genetic and biological associations for CAD, which could lead to the development of potentially

Address correspondence and reprint requests to: Hooman Allayee, PhD, Institute for Genetic Medicine, Keck School of Medicine, University of Southern California, 2250 Alcazar Street, CSC202, Los Angeles, CA 90033, Phone: (323) 442-1736, Fax: (332) 442-2764, hallayee@usc.edu.

Conflicts of Interest
None.

novel therapeutic strategies. Other important areas of investigation for understanding the pathophysiology of CAD, including epistatic interactions between genes or with either sex and environmental factors, have not been studied on a broad scope and represent additional opportunities for future studies.

Keywords

coronary artery disease; genome-wide association study; rare variants; microbiome; metabolomics; gene-environment interactions

Introduction

Coronary artery disease (CAD) and other forms of cardiovascular disease remain the number one cause of death for both men and women in Western societies[1], even in the contemporary era of high-potency statin therapy[2]. Individuals with CAD are typically asymptomatic, with the first manifestations of this pathogenic condition being clinically significant endpoints such as myocardial infarction (MI). It is generally accepted that CAD is characterized by lifetime exposure to an atherogenic environment in the context of genetic susceptibility factors. In this regard, large-scale studies in human populations and rapid advances in genetic technologies over the last several years have revolutionized our understanding of the genetic basis of CAD. However, the susceptibility alleles identified to date, most of which are common in the population, still only explain a small fraction of the overall heritability for CAD. This observation implies either the existence of additional variants with smaller effect sizes, higher order interactions between genes and environmental factors, rare susceptibility alleles, and/or other unknown biological/genetic mechanisms. In this review, we highlight recent discoveries that provide a framework for our current understanding of the genetic etiology of CAD. We also discuss areas of investigation that provide opportunities for further expansion of our knowledge and/or translation to improved clinical care.

Contribution of Common Genetic Variants to CAD and Clinically Associated Risk Factors

Beginning with the first genome-wide association studies (GWAS) [3–6], gene finding efforts over the last decade have transformed our understanding of the genetic architecture of CAD. The majority of these GWAS have been in individuals of European descent and have investigated various blood biomarkers that are associated with clinical disease as well discrete CAD phenotypes. For example, the most recent meta-analysis carried out by the CARDIoGRAMplusC4D Consortium, which included ~185,000 cases and controls, revealed ~50 distinct loci that were associated with CAD at the genome-wide significance threshold (Table 1)[7••]. Another 10 regions were identified that exhibited nominally significant associations as well [7••]. Meta-analysis of GWAS data in large numbers of subjects have also been carried out for numerous quantitative phenotypes clinically associated with CAD, including conventional risk factors, such as lipid levels and blood pressure, as well as less traditional biomarkers related to other biological mechanisms, such as inflammation, oxidation, coagulation, and amino acid metabolism. Depending on the sample size used,

dozens to hundreds of genes have been identified for each respective biomarker[8]. Thus, there is wealth of data already generated and, to the credit of the genetic research community and various consortia involved, many of the datasets are freely accessibly for other investigators to mine and use in their own analyses.

Whether for CAD phenotypes or related biomarkers, several important insights can be gleaned from the results of these genetic studies. First, the evidence clearly confirms the hypothesis that common variants contribute to common diseases/complex traits. However, the CAD loci with the strongest genetic effects, such as *SLC22A3-LPAL2-LPA* and chromosome 9p21, still only confer a 20–37% increased risk and the vast majority of the loci modulate risk by 10% or less (Table 1). Furthermore, the ~60 loci for CAD collectively explain <20% of the heritability, raising the question of where to search for the remaining genetic risk. Second, with the exception of the dozen or so regions that harbor genes known to be involved in CAD-related pathways(i.e. lipids or blood pressure), the biological mechanisms through which most of these loci affect atherosclerosis or its clinical biomarkers are not evident and remain a challenge to decipher. This is compounded by the fact that the identified loci often exhibit extensive linkage disequilibrium (LD) between variants and harbor multiple genes, which make it difficult to identify the underlying causal genes/variants simply from the GWAS results alone. One approach to overcome this difficulty has been to use trans-ethnic analyses. This was based on the assumption that causal variants would be shared among different populations, but the shorter LD blocks in subjects of African ancestry, for example, would improve mapping resolution and possibly even identify additional ethnicity-specific risk loci. CAD-associated regions were generally found to be concordant between subjects of European or Asian ancestry, but most loci failed to replicate or showed considerably reduced effect sizes in African ancestry populations [9, 10]. While the smaller sample sizes used for non-European ancestry subjects could have decreased statistical power, these observations also raise the possibility that the genetic mechanisms leading to CAD are different in subjects of African ancestry compared to Eurasian populations.

Computational and Bioinformatics Approaches for Identifying Causal Biological Pathways and Positional Candidate Genes

Beyond just GWAS analyses, investigators have developed and applied various computational and bioinformatics methods to identify causal biological pathways and prioritize positional candidate genes. Although the gold standard for determining causality with biomarkers has relied on randomized clinical trials, Mendelian randomization with GWAS data has also emerged as highly useful tool for determining the causal relationship between clinical biomarkers and CAD [reviewed extensively in ref.[11]]. The central tenet behind this approach is that a genetic variant leads to natural randomization of individuals to high or low biomarker levels. In the absence of pleiotropic effects of the variant, it follows that if a biomarker is a causal driver of disease, the genetic determinants of the biomarker will also be associated with disease risk.

Based on this premise, Mendelian randomization and genetic studies have confirmed the causal relationship between CAD and certain classic risk factors, including blood pressure [12, 13], low-density lipoprotein (LDL) cholesterol [14, 15], triglycerides [16], obesity [17], and type 2 diabetes [18–20], and pointed to novel causal associations with interesting traits, such as telomere length [21] and height [22]. However, these analyses also highlight several notable exceptions. For example, chronic kidney disease [23], fibrinogen [24], high-density lipoprotein (HDL) cholesterol [14], homocysteine [25], or uric acid [26] do not appear to be casually related to CAD. With the exception of IL-6 receptor signaling [27, 28], genetic analyses do not support causal roles for inflammatory biomarkers either, including C-reactive protein (CRP) [29, 30], ceruloplasmin [31], myeloperoxidase [32], and paraoxonase [33].

Other bioinformatics analyses have also been informative for interrogating GWAS data and providing additional biological insight in the pathogenesis of CAD. One such widely used approach has been the integration of transcriptomics in so called expression quantitative trait locus (eQTL) analysis. An eQTL is defined as a SNP that affects transcript levels of a nearby (*cis*) or distant (*trans*) gene, and its coincident mapping with an association signal for a clinical phenotype provides strong evidence that the given SNP has a functional effect. eQTL analyses are now easily facilitated by publicly available multi-tissue datasets [34] and, in their simplest application, can be used to narrow down the number of positional candidates at GWAS loci by focusing on those genes for which an eQTL is observed. More sophisticated network analyses have also been carried out with eQTL data. As demonstrated recently, SNPs associated with cardiometabolic risk yielded more *cis* and *trans* eQTLs in vascular and metabolic tissues from CAD patients compared to eQTLs from tissues of healthy subjects, with some of the eQTLs even being tissue specific [35].

Other computational approaches have involved pathway analyses with GWAS data. For example, a gene-set enrichment-based analysis revealed several core biological processes that were associated with CAD, including those related to extracellular matrix integrity, innate immunity, and growth factor signaling [36]. Another recent study incorporated multiple bioinformatics approaches by intersecting all transcript-coding genes at CAD-associated loci identified in GWAS with lead variants and proxy SNPs at these loci that were either deleterious amino acid changes, yielded eQTLs, or were located in putative regulatory regions [37]. The results of these integrative analyses led to the conclusion that the great majority of causal variation at loci for risk of CAD occur in noncoding regions and that genetic variants at these loci affect 98 genes that were not previously linked to CAD. A similar integrative analysis revealed that a transcriptional network linking multiple independent CAD loci is regulated by TCF21 [38]. However, it should be noted that while such studies have provided additional insight into the biology of CAD, they are still hypothesis generating and require experimental follow up to validate the inferred associations.

Evidence that Rare Variants Influence Risk of CAD

Rare variants, typically defined as those with <1% frequency in the population, have been postulated to be one piece of the puzzle for the so-called "missing heritability" of CAD.

Since rare variants are generally not captured on GWAS chips or easy to impute, investigators have turned to other approaches for determining whether they are associated with risk of CAD. Utilizing family-based studies, targeted re-sequencing of candidate genes, whole exome or genome sequence analyses, or a chip-based array containing pre-selected exonic variants, several genes have been found to harbor rare variants that modulate risk of CAD (Table 2).

In one study, analysis of an extended German pedigree revealed a digenic pattern of inheritance where family members with early-onset MI (60 years of age) were more likely to be heterozygous for protein altering mutations in *GUCY1A3* and *CCT7* [39]. The biological mechanism for how *GUCY1A3* and *CCT7* increase risk of MI appears to involve nitric oxide signaling and platelet function (Table 2). Targeted re-sequencing of candidate genes have also revealed rare variants that are associated with risk of CAD through lipid metabolism pathways. One of the first successful examples of this approach was the identification of rare loss-of-function variants in *PCSK9* that lowered LDL cholesterol levels and conferred protection against CAD [40]. Notably, *PCSK9* was originally identified in a family-based genetics study where gain-of-function mutations were shown to be the cause of autosomal dominant hypercholesterolemia [41]. More recent targeted re-sequencing studies demonstrated that loss-of-function mutations of *APOC3* and *ANGPTL4* decreased risk of CAD through lowering of plasma triglyceride levels [42, 43]. By contrast, a loss-of-function mutation in *SCARB1*, which mediates selective hepatic uptake of HDL particles, led to elevated plasma HDL cholesterol levels and, surprisingly, increased risk of CAD [44•] (Table 2).

A more agnostic approach to identifying rare variants has been to comprehensively interrogate the coding portion of the genome through whole-exome sequencing. These efforts identified rare variants in *APOC3* as well as *APOA5*, *LDLR*, and *NPC1L1* that modulated risk of CAD or MI through their effects on triglyceride or cholesterol metabolism [45–47] (Table 2). Extending this unbiased strategy to whole-genome sequencing also revealed that subjects heterozygous for a 12bp deletion in *ASGR1,* which encodes a subunit of a lectin that plays a role in the homeostasis of circulating glycoproteins, had lower non-HDL cholesterol levels and reduced risk of CAD [48]. Lastly, another complementary approach has been to evaluate the contribution of low-frequency coding variation to CAD through the use of a customized exome array. While this strategy is limited to pre-selected variants, it is more cost-effective compared to exome or whole-genome sequencing and thus provides the advantage of including large sample sizes. Using the exome array, previously reported associations of low-frequency missense variants in *PCSK9* and *LPA* with CAD were confirmed [40, 49, 50]. Significant associations with either increased or decreased risk of CAD, depending on the biological consequence of the variant, were also observed with *ANGPTL4*, *LPL*, and *SVEP1* [50] (Table 2). Interestingly, the missense substitution in *SVEP1*, which encodes a cell adhesion molecule, was associated with a very modest increase in systolic and diastolic blood pressure. Since this effect alone cannot explain the magnitude of the association with increased risk of CAD, it suggests the existence of additional unknown and potentially novel genetic mechanisms leading to atherosclerosis [50].

Taken together, the results of rare variant studies illustrated several interesting concepts. As might be expected, the effect sizes of the identified variants on intermediate lipid traits and risk of CAD were, for the most part, larger compared to those for common variants identified in GWAS. However, it also became apparent that low frequency polymorphisms collectively still only explain a very small proportion of the heritability for CAD, suggesting that a significant fraction of genetic susceptibility to CAD is unlikely to reside in rare variation. Lastly, most of the identified genes were in pathways already known to be involved in the pathogenesis of CAD, such as lipid metabolism. However, the results of these rare variant studies did support the notion that triglycerides are causally associated with the development of CAD, which corroborate the results of Mendelian randomization studies.

Insight from Genetic Studies in Mice

Given the difficulties in human genetic studies, mouse models provide another strategy for gene discovery that can be extrapolated to humans as well as a model system for understanding the mechanisms underlying CAD-related phenotypes. Most atherosclerosis studies in mice have focused on perturbing specific candidate genes on genetically hyperlipidemic backgrounds [51], with hundreds of genes being reported in the literature as modulating aortic lesion formation. However, a systematic review of results from these mouse knockout or transgenic studies and human GWAS revealed surprisingly little evidence that atherosclerosis-causing genes in mice are associated with risk of CAD in humans [52]. It is worth noting that the human GWAS results used for this comparison were from a prior meta-analysis [53] that included approximately half the number of subjects as the most recent study from the CARDIoGRAMplusC4D Consortium discussed above [7••]. Furthermore, overexpression or complete deficiency of single genes in mice may not represent the subtle genetic perturbations that are likely to underlie common forms of CAD in humans, thus rendering such comparative genomics analyses difficult.

An alternative approach with mouse models is to exploit naturally occurring genetic variation among inbred strains, analogous to studies in human populations. In this regard, a genetics platform was recently developed for GWAS in mice [54], termed the Hybrid Mouse diversity panel (HMDP). Since each strain is renewable, diverse molecular, proteomic, metabolomic, and clinical phenotypic data can be collected *ad infinitum* in multiple mice of the same strain/genotype, thus facilitating systems genetics analyses. Studies with the HMDP have been applied to a variety of traits relevant to human CAD and consistently identified positional candidate genes for follow-up functional experiments [55–61].

To specifically examine atherosclerosis in the HMDP, an F1 hybrid strategy was used where the dominant-acting and atherosclerosis-promoting transgenes, human apolipoprotein E-Leiden (APOE-Leiden) and human cholesteryl ester transfer protein (CETP), were bred from strain C57BL/6J onto over 100 hundred different strains in the HMDP [62]. In addition to aortic lesion formation, global gene expression profiling was carried out and levels of clinically relevant biomarkers were measured in plasma. Systems genetics analyses led to several interesting conclusions. For example, the relationships between atherosclerosis and CAD-related risk factors in mice resembled those found in humans [62], and the combined

variations in plasma levels of LDL/VLDL-cholesterol, glucose, insulin, and various other metabolites accounted for approximately 30 to 40% of the variation in aortic lesion formation. Additionally, broad sense heritability for atherosclerosis was much larger than narrow sense heritability and the ratio of lesion size between male and female mice varied extensively among the strains [62]. These observations indicate the existence of both gene-gene and gene-sex interactions. Lastly, some of the loci mapped by GWAS in the HMDP overlapped with those previously identified in human and mouse studies [62]. The advantage of having gene expression data in several atherosclerosis-relevant tissues, such as aorta, liver, and adipose, also enabled enrichment analysis of pathways contributing to atherosclerosis and prioritization of candidate genes at associated loci in both mice and humans. Collectively, these data provide a rich resource that can be further leveraged for understanding the complex interactions underlying atherosclerosis and provide new directions that can be explored in future human genetics studies.

Role of Intestinal Microbiota in the Development of CAD

It has become widely appreciated that our gut symbionts play integral roles in human health since perturbations of this bacterial community or the products they can produce have been associated with increased susceptibility to a variety of diseases. The first indications of these associations were for colitis and inflammatory bowel disease, but altered gut microbial composition or function has now been shown to affect various cardiometabolic phenotypes that could subsequently affect risk of CAD, such as lipid metabolism and obesity-related metabolic abnormalities [63–69].

A more direct role for intestinal microbes in the development of atherosclerosis was recently demonstrated by the identification of a novel meta-organismal pathway involving multiple interactions between gut bacteria, dietary nutrients, and host metabolism [70–75]. These studies revealed a mechanism whereby bacterial metabolism of dietary choline and L-carnitine in the intestine leads to the formation of an intermediate, trimethylamine (TMA), which is absorbed from the gut and subsequently oxidized by one or more hepatic flavin monooxygenases (FMOs) to generate trimethylamine *N*-oxide (TMAO) [71, 76]. Plasma TMAO levels were positively associated with aortic lesion formation in mice and increased risk of prevalent/incident CAD in humans, the effects of which could be mediated, at least in part, through foam cell formation, reverse cholesterol transport, bile acid metabolism, and platelet hyperresponsiveness [70, 72, 73, 77–79].

One important question raised by these studies is whether intrinsic host genetic variants are associated with plasma TMAO levels and, by extension, risk of CAD. While GWAS analyses with the HMDP identified three loci [62, 80], two GWAS in humans failed to identify loci significantly associated with TMAO levels [80, 81], thus precluding the determination of its causal nature with CAD with the use of a genetic instrument in Mendelian randomization analyses. Taken together, these studies suggest that the contribution of host genetic factors to plasma TMAO levels are relatively weak and/or complex, at least in humans, and that variation in diet or the repertoire of gut microbiota may be more important determinants. Interestingly, studies in humans have uncovered a surprising number of associations between genetic variants and the abundance of various

bacterial taxa [82–86]. This concept is supported by a separate HMDP obesity study, which identified seven host loci that were associated with common bacterial genera [87•]. Thus, it is possible that host genetic factors could control TMAO levels indirectly by regulating the abundance of TMA-generating bacteria. However, the existence of such loci in mice or humans remains to be determined.

Integrative Metabolomics and Genetics Reveals Novel Sex-specific Association with CAD

Metabolomics is an emerging field of biomedical research that is based on characterizing the repertoire of small molecules in biological samples. This has led to the identification of metabolites in several pathways that may serve as novel clinical biomarkers for CAD [88], such as those discussed above for TMAO. Furthermore, the availability of metabolic profiles with genomic, transcriptomic, proteomic, and clinical data have yielded comprehensive datasets that can potentially be leveraged in systems genetics analyses, similar to those implemented in the HMDP, to identify underlying biological networks that drive disease susceptibility [89]. However, such studies have generally been carried out in an unbiased fashion, both from a genetics and metabolomics perspective, and efforts are underway to intersect these high dimensional data to identify pathways causally related to CAD and other diseases.

Another complementary metabolomics strategy is to focus on targeted pathways that have been directly implicated in the development of CAD. This approach was exemplified by a recent study seeking to understand the relationship between CAD and betaine, another choline-derived metabolite that has also been associated with atherosclerosis in mouse models and increased risk of CAD in humans [70]. AGWAS for plasma betaine levels identified two significantly associated loci, one of which mapped to carbamoyl-phosphate synthase 1 (*CPS1*) on chromosome 2q34 [90•]. *CPS1* encodes a mitochondrial enzyme that catalyzes the first committed reaction and rate-limiting step in the urea cycle, raising the interesting question of how CPS1 would therefore be associated with betaine levels. This is best explained by a series of known stepwise demethylation reactions that metabolize betaine (also known as trimethylglycine) to glycine. The major catabolic route for glycine is through the glycine cleavage complex, which forms ammonia and metabolized by CPS1 to carbamoyl phosphate for entry into the urea cycle.

Based on previously reported effects of the *CPS1* locus [91], follow-up targeted metabolomics and genetic analyses revealed a distinctive sexually dimorphic pattern of pleiotropic associations with decreased levels of the most proximal precursors (i.e. choline, TMAO, and betaine) and the most distal urea cycle metabolites, such as citrulline, arginine, and ornithine [90•]. By comparison, the strongest and most significant metabolite association was observed with increased plasma glycine levels. Importantly, the *CPS1* locus also yielded a strikingly significant and protective association with risk of CAD in women but not men [90•]. This association represents one of the first female-specific genetic risk factors for CAD reported in the literature and its magnitude (~12% decreased risk) was equivalent to the most significantly associated loci identified for CAD to date [7••].

Taken together, the results of this study illustrate several important concepts that could be informative future studies. For example, given that the known loci for CAD still only explain <20% of the genetic variation in risk [7••], the association of *CPS1* with CAD in only women suggests that a portion of the "missing heritability" may also reside in sex-specific associations. This observation highlights the need for genetics studies of CAD and related biomarkers to be of sufficient size in order to permit adequately powered analyses in men and women separately. In addition, the *CPS1* locus had previously been associated with various other CAD-related traits [92, 93, 25, 94–99, 24], but the direction of the associations with these biomarkers was opposite to what would be expected for a variant that decreases risk of CAD [90•]. Thus, it is possible that the protective association with CAD is mediated through lower TMAO levels or increased glycine levels. In this regard, prior *in vitro* studies demonstrated that glycine has anti-inflammatory properties in endothelial cells, activated macrophages, and other leukocytes [100–104]. A recent clinical study also reported an inverse relationship between plasma glycine levels and risk of MI [105], consistent with the glycine-raising effects of *CPS1* and its cardioprotective association with CAD. Lastly, the association of *CPS1* with TMAO levels was modest compared to glycine levels, suggesting that TMAO may not be the likely causal metabolite [90•]. However, additional follow up studies will still be needed to replicate these findings and to determine whether the underlying causal mechanism(s) by which *CPS1* decreases risk of CAD is directly related to glycine metabolism or whether it involves TMAO, the urea cycle, or other unknown pathways/intermediates. More broadly, this study also suggests that integration of metabolomics in future genetic studies can potentially reveal novel pathways that are relevant to the development of CAD.

Translational and Clinical Implications of Genetic Studies

An important question from genetic studies of CAD is whether the findings can be leveraged towards development of novel therapeutic strategies. Notably, genetic studies can provide valuable insight into whether a drug target modulates a pathway that is causally related to the atherosclerosis. For example, although statins or ezetimibe were initially developed without the knowledge provided by genetic studies, their cardiovascular benefits were further validated when lipid-lowering variants of genes targeted by these drugs (*HMGCR* and *NPC1L1*) were shown to be associated with reduced risk of CAD [46, 15]. The initial identification of *PCSK9* as cause of autosomal dominant hypercholesterolemia [41], followed by the discovery of additional *PCSK9* variants that were associated with both LDL cholesterol levels and CAD [7••, 40, 50], has also advanced the development of several different classes of therapeutic agents that inhibit PCSK9 [106]. Two of these drugs (evolocumab and alirocumab) have already been approved for use in patients with familial hypercholesterolemia, statin intolerance, or insufficient LDL cholesterol control with statins [107, 108]. Furthermore, a recently published clinical trial with CAD patients demonstrated that the addition of evolocumab to statin therapy resulted insignificant regression of coronary plaque volume compared to patients receiving only on statins [109]. Similarly, and based on the cardioprotection conferred by loss-of-function variants of *APOC3* [42, 45], two phase 2 studies with an anti-sense inhibitor of *APOC3* demonstrated significant reductions of plasma triglycerides in patients with hypertriglyceridemia or type 2 diabetes without any

notable safety issues [110, 111]. By contrast, attempts to reduce risk of CAD by raising HDL cholesterol levels through inhibition of CETP has not been successful thus far [112, 113]. These null clinical effects are consistent with the results of genetic analyses that raised questions regarding the causal role of HDL cholesterol levels in the development of atherosclerosis [14, 44•]. However, it should be noted that inferring causality from Mendelian randomization studies alone can be difficult. For example, since the biological function of HDL cholesterol-associated variants are mostly unknown, they may have varying effects on CAD risk. In addition, circulating levels of HDL cholesterol per se may not be a good surrogate for the atheroprotective effects of HDL, leading to the hypothesis that HDL function and its cholesterol efflux capacity are better indicators. This notion is consistent with recent studies demonstrating inverse associations between cholesterol efflux and prevalent CAD and incident cardiovascular events [114, 115], although a separate study reported paradoxically opposite associations with prospective risk of MI, stroke, and death [116]. Thus, the nature of relationship between HDL levels/function and atherosclerosis has yet to be fully determined. Lastly, inflammatory pathways, and particularly those mediated by *IL6R*, have also been causally associated with atherosclerosis and provide additional therapeutic opportunities. For example, the interleukin 6 receptor (IL6R) antagonist tocilizumab is under consideration for treatment of CAD and is currently being evaluated for reducing cardiovascular risk in patients with rheumatoid arthritis [117, 118].

Another promising therapeutic avenue for CAD may involve selective manipulation of the gut microbial ecosystem by either altering bacterial composition or targeting biological processes specific to intestinal bacteria. Studies in mice have demonstrated that transplantation of cecal microbes from an atherosclerosis-prone strain with high TMA/ TMAO levels to a low TMAO-producing and atherosclerosis-resistant strain can enhance production of these pro-atherogenic metabolites with a corresponding increase in aortic lesion formation [75]. These observations raise the intriguing question of whether using the converse strategy with bacterial transplantation from individuals with low TMA/TMAO-producing capacity, such as vegans [72], can decrease risk of CAD. Although such approaches have yet to be implemented in humans with respect to CAD, fecal transplantation studies have shown that transfer of gut microbes from lean donors through a duodenal infusion into patients with metabolic syndrome can improve insulin sensitivity [119]. In another strategy, a small molecule choline analog, 3, 3-dimethyl-1-butanol (DMB), was designed to competitively inhibit diverse and phylogenetically distant classes of microbial TMA lyases, which were previously identified as enzymes that catalyze the conversion of choline to TMA [120, 121]. Chronic feeding of DMB to mice in the context of a high-choline diet led to shifts in the proportions of some bacterial taxa and substantial reductions in plasma TMAO levels, macrophage cholesterol accumulation, foam cell formation, and atherosclerotic lesions, without any evidence of toxicity or adverse cardiometabolic effects in the animals [122•]. Taken together, these results suggest that targeting gut microbial composition or production of bacterial-derived metabolites through transplantation or specific pharmacological manipulation may serve as potentially novel therapeutic approaches for treating CAD.

Opportunities and Areas of Investigation for Future Studies

Despite the advances made over the last several years, there is still much that we do not know about the genetic basis of CAD. As noted above, one looming question is the large fraction of the heritability that cannot be explained by the genetic discoveries thus far. It is possible that heritability of CAD is over-estimated but it is also likely that epistatic interactions between genes (GxG) or gene-environment(GxE) and gene-sex interactions play important roles in determining risk of CAD as well. However, GxG and GxE analyses have proven difficult, particularly on a genome-wide level, because of the requirements for both genotype and exposure data, and, with respect to GxE interactions, imprecise exposure assessment. In this regard, diet and smoking are well known environmental exposures relevant to risk of CAD, and there is a large body of epidemiological data showing consistent adverse associations with ambient air pollution as well [123]. However, obtaining accurate measures of dietary intake or air pollution exposure in large numbers of subjects are difficult and have hindered progress in this area. Nonetheless, GxG and GxE interactions for CAD represent excellent opportunities for future studies if methodological and statistical challenges can be overcome.

Elucidating the molecular mechanisms for the association of variants with CAD represents another area that is being actively pursued but is laborious and often requires extensive experimental follow up. For example, despite being identified nearly 10 years ago, it is only recently and partially being understood how the 9p21 locus influences risk of CAD [124]. This novel atherogenic mechanism appears to involve the regulation of ribosome biogenesis in vascular smooth muscle cells and macrophages by a circular non-coding RNA encoded by *CDKN2B-AS* that is transcribed from the 9p21 locus [124]. Since most loci for CAD or causally associated biomarkers fall within non-coding regions, the availability of HAPMAP, ENCODE, and multi-tissue eQTL data should facilitate the identification candidate genes that could be studied further with mouse models or evaluated as therapeutic targets.

Conclusions

In summary, recent efforts to elucidate the genetic architecture of CAD have revealed multiple mechanisms that contribute to the pathogenesis of atherosclerosis (Figure 1). There is ample evidence that common genetic variants influence risk of CAD via perturbations of lipid metabolism, blood pressure, inflammation, platelet function, as well as other unknown biological pathways that have yet to delineated. However, evidence from studies evaluating the contribution of rare variants is less compelling, although it should be noted that studies determining the effects of rare variant can be hampered by inadequate power. While some novel genes have been identified, mostly related to lipid metabolism, it does not appear that low frequency variation explain a significant portion of the "missing heritability" that has thus far remained elusive. In addition, the realization that metabolic interactions between the microbiome and dietary nutrients can promote the development of CAD provides excellent opportunities for furthering our understanding of the atherosclerotic process. By comparison, the cross talk between genes and with environmental factors or sex have not been explored to the same degree as the search for main effects even though these interactions are also likely to be important components in determining the overall risk for

CAD. Taken together, genetic discoveries made over the last several years offer new avenues for further research and therapeutic development that will have a fundamental impact on our understanding of the atherosclerosis and the treatment of patients with CAD.

Acknowledgments

References

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation. 2014; 129(3):e28–e292. DOI: 10.1161/01.cir.0000441139.02102.80 [PubMed: 24352519]

2. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008; 359(21):2195–207. DOI: 10.1056/NEJMoa0807646 [PubMed: 18997196]

3. Helgadottir A, Thorleifsson G, Manolescu A, Gretarsdottir S, Blondal T, Jonasdottir A, et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science. 2007; 316(5830):1491–3. DOI: 10.1126/science.1142842 [PubMed: 17478679]

4. McPherson R, Pertsemlidis A, Kavaslar N, Stewart A, Roberts R, Cox DR, et al. A common allele on chromosome 9 associated with coronary heart disease. Science. 2007; 316(5830):1488–91. DOI: 10.1126/science.1142447 [PubMed: 17478681]

5. Samani NJ, Erdmann J, Hall AS, Hengstenberg C, Mangino M, Mayer B, et al. Genomewide association analysis of coronary artery disease. N Engl J Med. 2007; 357(5):443–53. DOI: 10.1056/NEJMoa072366 [PubMed: 17634449]

6. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007; 447(7145):661–78. [PubMed: 17554300]

7••. Nikpay M, Goel A, Won HH, Hall LM, Willenborg C, Kanoni S, et al. A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease. Nat Genet. 2015; 47(10):1121–30. This study represents the largest and most up-to-date meta-analysis of GWAS data for coronary artery disease with >180,000 subjects and identified ~60 risk loci. DOI: 10.1038/ng.3396 [PubMed: 26343387]

8. Welter D, MacArthur J, Morales J, Burdett T, Hall P, Junkins H, et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. Nucleic Acids Res. 2014; 42(Database issue):D1001–6. DOI: 10.1093/nar/gkt1229 [PubMed: 24316577]

9. Marigorta UM, Navarro A. High trans-ethnic replicability of GWAS results implies common causal variants. PLoS Genet. 2013; 9(6):e1003566.doi: 10.1371/journal.pgen.1003566 [PubMed: 23785302]

10. Carlson CS, Matise TC, North KE, Haiman CA, Fesinmeyer MD, Buyske S, et al. Generalization and dilution of association results from European GWAS in populations of non-European ancestry: the PAGE study. PLoS Biol. 2013; 11(9):e1001661.doi: 10.1371/journal.pbio.1001661 [PubMed: 24068893]

11. Jansen H, Lieb W, Schunkert H. Mendelian randomization for the identification of causal pathways in atherosclerotic vascular disease. Cardiovasc Drugs Ther. 2016; 30(1):41–9. DOI: 10.1007/s10557-016-6640-y [PubMed: 26791863]

12. Lieb W, Jansen H, Loley C, Pencina MJ, Nelson CP, Newton-Cheh C, et al. Genetic predisposition to higher blood pressure increases coronary artery disease risk. Hypertension. 2013; 61(5):995–1001. DOI: 10.1161/HYPERTENSIONAHA.111.00275 [PubMed: 23478099]

13. Kato N, Loh M, Takeuchi F, Verweij N, Wang X, Zhang W, et al. Trans-ancestry genome-wide association study identifies 12 genetic loci influencing blood pressure and implicates a role for DNA methylation. Nat Genet. 2015; 47(11):1282–93. DOI: 10.1038/ng.3405 [PubMed: 26390057]

14. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. 2012; 380(9841):572–80. DOI: 10.1016/S0140-6736(12)60312-2 [PubMed: 22607825]

15. Ference BA, Majeed F, Penumetcha R, Flack JM, Brook RD. Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2×2 factorial Mendelian randomization study. J Am Coll Cardiol. 2015; 65(15):1552–61. DOI: 10.1016/j.jacc.2015.02.020 [PubMed: 25770315]

16. Do R, Willer CJ, Schmidt EM, Sengupta S, Gao C, Peloso GM, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet. 2013; 45(11):1345–52. DOI: 10.1038/ng.2795 [PubMed: 24097064]

17. Nordestgaard BG, Palmer TM, Benn M, Zacho J, Tybjaerg-Hansen A, Davey Smith G, et al. The effect of elevated body mass index on ischemic heart disease risk: causal estimates from a Mendelian randomisation approach. PLoS Med. 2012; 9(5):e1001212.doi: 10.1371/journal.pmed. 1001212 [PubMed: 22563304]

18. Ahmad OS, Morris JA, Mujammami M, Forgetta V, Leong A, Li R, et al. A Mendelian randomization study of the effect of type-2 diabetes on coronary heart disease. Nat Commun. 2015; 6:7060.doi: 10.1038/ncomms8060 [PubMed: 26017687]

19. Jansen H, Loley C, Lieb W, Pencina MJ, Nelson CP, Kathiresan S, et al. Genetic variants primarily associated with type 2 diabetes are related to coronary artery disease risk. Atherosclerosis. 2015; 241(2):419–26. DOI: 10.1016/j.atherosclerosis.2015.05.033 [PubMed: 26074316]

20. Ross S, Gerstein HC, Eikelboom J, Anand SS, Yusuf S, Pare G. Mendelian randomization analysis supports the causal role of dysglycaemia and diabetes in the risk of coronary artery disease. Eur Heart J. 2015; 36(23):1454–62. DOI: 10.1093/eurheartj/ehv083 [PubMed: 25825043]

21. Codd V, Nelson CP, Albrecht E, Mangino M, Deelen J, Buxton JL, et al. Identification of seven loci affecting mean telomere length and their association with disease. Nat Genet. 2013; 45(4): 422–7. 7e1–2. DOI: 10.1038/ng.2528 [PubMed: 23535734]

22. Nelson CP, Hamby SE, Saleheen D, Hopewell JC, Zeng L, Assimes TL, et al. Genetically determined height and coronary artery disease. N Engl J Med. 2015; 372(17):1608–18. DOI: 10.1056/NEJMoa1404881 [PubMed: 25853659]

23. Olden M, Teumer A, Bochud M, Pattaro C, Kottgen A, Turner ST, et al. Overlap between common genetic polymorphisms underpinning kidney traits and cardiovascular disease phenotypes: the CKDGen consortium. Am J Kidney Dis. 2013; 61(6):889–98. DOI: 10.1053/j.ajkd.2012.12.024 [PubMed: 23474010]

24. Sabater-Lleal M, Huang J, Chasman D, Naitza S, Dehghan A, Johnson AD, et al. Multiethnic meta-analysis of genome-wide association studies in >100 000 subjects identifies 23 fibrinogen-associated loci but no strong evidence of a causal association between circulating fibrinogen and cardiovascular disease. Circulation. 2013; 128(12):1310–24. DOI: 10.1161/CIRCULATIONAHA. 113.002251 [PubMed: 23969696]

25. van Meurs JB, Pare G, Schwartz SM, Hazra A, Tanaka T, Vermeulen SH, et al. Common genetic loci influencing plasma homocysteine concentrations and their effect on risk of coronary artery disease. Am J Clin Nutr. 2013; 98(3):668–76. DOI: 10.3945/ajcn.112.044545 [PubMed: 23824729]

26. Palmer TM, Nordestgaard BG, Benn M, Tybjaerg-Hansen A, Davey Smith G, Lawlor DA, et al. Association of plasma uric acid with ischaemic heart disease and blood pressure: mendelian randomisation analysis of two large cohorts. BMJ. 2013; 347:f4262.doi: 10.1136/bmj.f4262 [PubMed: 23869090]

27. Sarwar N, Butterworth AS, Freitag DF, Gregson J, Willeit P, Gorman DN, et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet. 2012; 379(9822):1205–13. [PubMed: 22421339]

28. Interleukin-6 Receptor Mendelian Randomisation Analysis Consortium. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet. 2012; 379(9822):1214–24. DOI: 10.1016/S0140-6736(12)60110-X [PubMed: 22421340]

29. Dehghan A, Dupuis J, Barbalic M, Bis JC, Eiriksdottir G, Lu C, et al. Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels. Circulation. 2011; 123(7):731–8. [PubMed: 21300955]

30. Wensley F, Gao P, Burgess S, Kaptoge S, Di Angelantonio E, Shah T, et al. Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. BMJ. 2011; 342:d548. [PubMed: 21325005]

31. Tang WH, Wu Y, Hartiala J, Fan Y, Stewart AF, Roberts R, et al. Clinical and genetic association of serum ceruloplasmin with cardiovascular risk. Arterioscler Thromb Vasc Biol. 2012; 32(2):516–22. [PubMed: 22075249]

32. Reiner AP, Hartiala J, Zeller T, Bis JC, Dupuis J, Fornage M, et al. Genome-wide and gene-centric analyses of circulating myeloperoxidase levels in the CHARGE and CARe consortia. Hum Mol Genet. 2013; 22(16):3381–93. [PubMed: 23620142]

33. Tang WH, Hartiala J, Fan Y, Wu Y, Stewart AF, Erdmann J, et al. Clinical and genetic association of serum paraoxonase and arylesterase activities with cardiovascular risk. Arterioscler Thromb Vasc Biol. 2012; 32(11):2803–12. [PubMed: 22982463]

34. The Genotype-Tissue Expression Consortium. Human genomics. The genotype-tissue expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science. 2015; 348(6235):648–60. DOI: 10.1126/science.1262110 [PubMed: 25954001]

35. Franzen O, Ermel R, Cohain A, Akers NK, Di Narzo A, Talukdar HA, et al. Cardiometabolic risk loci share downstream cis- and trans-gene regulation across tissues and diseases. Science. 2016; 353(6301):827–30. DOI: 10.1126/science.aad6970 [PubMed: 27540175]

36. Ghosh S, Vivar J, Nelson CP, Willenborg C, Segre AV, Makinen VP, et al. Systems genetics analysis of genome-wide association study reveals novel associations between key biological processes and coronary artery disease. Arterioscler Thromb Vasc Biol. 2015; 35(7):1712–22. DOI: 10.1161/ATVBAHA.115.305513 [PubMed: 25977570]

37. Braenne I, Civelek M, Vilne B, Di Narzo A, Johnson AD, Zhao Y, et al. Prediction of causal candidate genes in coronary artery disease loci. Arterioscler Thromb Vasc Biol. 2015; 35(10): 2207–17. DOI: 10.1161/ATVBAHA.115.306108 [PubMed: 26293461]

38. Sazonova O, Zhao Y, Nurnberg S, Miller C, Pjanic M, Castano VG, et al. Characterization of tcf21 downstream target regions identifies a transcriptional network linking multiple independent coronary artery disease loci. PLoS Genet. 2015; 11(5):e1005202.doi: 10.1371/journal.pgen. 1005202 [PubMed: 26020271]

39. Erdmann J, Stark K, Esslinger UB, Rumpf PM, Koesling D, de Wit C, et al. Dysfunctional nitric oxide signalling increases risk of myocardial infarction. Nature. 2013; 504(7480):432–6. DOI: 10.1038/nature12722 [PubMed: 24213632]

40. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006; 354(12):1264–72. [PubMed: 16554528]

41. Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, Devillers M, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003; 34(2):154–6. DOI: 10.1038/ ng1161 [PubMed: 12730697]

42. Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjaerg-Hansen A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med. 2014; 371(1):32–41. DOI: 10.1056/NEJMoa1308027 [PubMed: 24941082]

43. Dewey FE, Gusarova V, O'Dushlaine C, Gottesman O, Trejos J, Hunt C, et al. Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease. N Engl J Med. 2016; 374(12):1123–33. DOI: 10.1056/NEJMoa1510926 [PubMed: 26933753]

•44. Zanoni P, Khetarpal SA, Larach DB, Hancock-Cerutti WF, Millar JS, Cuchel M, et al. Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease. Science. 2016; 351(6278):1166–71. Using a variety of approaches, this study identified rare variants of *SRB1* that were associated with increased HDL cholesterol levels and increased risk of coronary artery diseaase. DOI: 10.1126/science.aad3517 [PubMed: 26965621]

45. Crosby J, Peloso GM, Auer PL, et al. TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute. Loss-of-function mutations in APOC3,

triglycerides, and coronary disease. N Engl J Med. 2014; 371(1):22–31. DOI: 10.1056/ NEJMoa1307095 [PubMed: 24941081]

46. Stitziel NO, Won HH, Morrison AC, Peloso GM, Do R, et al. Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia Investigators. Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med. 2014; 371(22):2072–82. DOI: 10.1056/ NEJMoa1405386 [PubMed: 25390462]

47. Do R, Stitziel NO, Won HH, Jorgensen AB, Duga S, Angelica Merlini P, et al. Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. Nature. 2015; 518(7537):102–6. DOI: 10.1038/nature13917 [PubMed: 25487149]

48. Nioi P, Sigurdsson A, Thorleifsson G, Helgason H, Agustsdottir AB, Norddahl GL, et al. Variant ASGR1 associated with a reduced risk of coronary artery disease. N Engl J Med. 2016; 374(22): 2131–41. DOI: 10.1056/NEJMoa1508419 [PubMed: 27192541]

49. Luke MM, Kane JP, Liu DM, Rowland CM, Shiffman D, Cassano J, et al. A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease. Arterioscler Thromb Vasc Biol. 2007; 27(9):2030–6. DOI: 10.1161/ATVBAHA.107.141291 [PubMed: 17569884]

50. Stitziel NO, Stirrups KE, Masca NG, Erdmann J, et al. Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia Investigators. Coding variation in ANGPTL4, LPL, and SVEP1 and the risk of coronary disease. N Engl J Med. 2016; 374(12):1134–44. DOI: 10.1056/ NEJMoa1507652 [PubMed: 26934567]

51. Getz GS, Reardon CA. Do the Apoe−/− and Ldlr−/− mice yield the same insight on atherogenesis? Arterioscler Thromb Vasc Biol. 2016; 36(9):1734–41. DOI: 10.1161/ATVBAHA.116.306874 [PubMed: 27386935]

52. Pasterkamp G, van der Laan SW, Haitjema S, Foroughi Asl H, Siemelink MA, Bezemer T, et al. Human validation of genes associated with a murine atherosclerotic phenotype. Arterioscler Thromb Vasc Biol. 2016; 36(6):1240–6. DOI: 10.1161/ATVBAHA.115.306958 [PubMed: 27079880]

53. Schunkert H, Konig IR, Kathiresan S, Reilly MP, Assimes TL, Holm H, et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet. 2011; 43(4):333–8. [PubMed: 21378990]

54. Bennett BJ, Farber CR, Orozco L, Min Kang H, Ghazalpour A, Siemers N, et al. A high-resolution association mapping panel for the dissection of complex traits in mice. Genome Res. 2010; 20(2): 281–90. [PubMed: 20054062]

55. Ghazalpour A, Bennett B, Petyuk VA, Orozco L, Hagopian R, Mungrue IN, et al. Comparative analysis of proteome and transcriptome variation in mouse. PLoS Genet. 2011; 7(6):e1001393. [PubMed: 21695224]

56. Bennett BJ, Orozco L, Kostem E, Erbilgin A, Dallinga M, Neuhaus I, et al. High-resolution association mapping of atherosclerosis loci in mice. Arterioscler Thromb Vasc Biol. 2012; 32(8): 1790–8. [PubMed: 22723443]

57. Orozco LD, Bennett BJ, Farber CR, Ghazalpour A, Pan C, Che N, et al. Unraveling inflammatory responses using systems genetics and gene-environment interactions in macrophages. Cell. 2012; 151(3):658–70. [PubMed: 23101632]

58. Davis RC, van Nas A, Bennett B, Orozco L, Pan C, Rau CD, et al. Genome-wide association mapping of blood cell traits in mice. Mamm Genome. 2013; 24(3–4):105–18. [PubMed: 23417284]

59. Parks BW, Nam E, Org E, Kostem E, Norheim F, Hui ST, et al. Genetic control of obesity and gut microbiota composition in response to high-fat, high-sucrose diet in mice. Cell Metab. 2013; 17(1):141–52. [PubMed: 23312289]

60. Ghazalpour A, Bennett BJ, Shih D, Che N, Orozco L, Pan C, et al. Genetic regulation of mouse liver metabolite levels. Molecular systems biology. 2014; 10(5):730.doi: 10.15252/msb.20135004 [PubMed: 24860088]

61. Zhou X, Crow AL, Hartiala J, Spindler TJ, Ghazalpour A, Barsky LW, et al. The genetic landscape of hematopoietic stem cell frequency in mice. Stem Cell Reports. 2015; 5(1):125–38. DOI: 10.1016/j.stemcr.2015.05.008 [PubMed: 26050929]

62. Bennett BJ, Davis RC, Civelek M, Orozco L, Wu J, Qi H, et al. Genetic architecture of atherosclerosis in mice: A systems genetics analysis of common inbred strains. PLoS Genet. 2015; 11(12):e1005711.doi: 10.1371/journal.pgen.1005711 [PubMed: 26694027]

63. Backhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A. 2004; 101(44):15718–23. DOI: 10.1073/pnas.0407076101 [PubMed: 15505215]

64. Dumas ME, Barton RH, Toye A, Cloarec O, Blancher C, Rothwell A, et al. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci U S A. 2006; 103(33):12511–6. DOI: 10.1073/pnas.0601056103 [PubMed: 16895997]

65. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006; 444(7122):1027–31. DOI: 10.1038/nature05414 [PubMed: 17183312]

66. Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012; 490(7418):55–60. DOI: 10.1038/nature11450 [PubMed: 23023125]

67. Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012; 482(7384):179–85. DOI: 10.1038/nature10809 [PubMed: 22297845]

68. Karlsson FH, Tremaroli V, Nookaew I, Bergstrom G, Behre CJ, Fagerberg B, et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature. 2013; 498(7452):99–103. DOI: 10.1038/nature12198 [PubMed: 23719380]

69. Fu J, Bonder MJ, Cenit MC, Tigchelaar EF, Maatman A, Dekens JA, et al. The gut microbiome contributes to a substantial proportion of the variation in blood lipids. Circ Res. 2015; 117(9):817–24. DOI: 10.1161/CIRCRESAHA.115.306807 [PubMed: 26358192]

70. Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011; 472(7341):57–63. [PubMed: 21475195]

71. Bennett BJ, de Aguiar Vallim TQ, Wang Z, Shih DM, Meng Y, Gregory J, et al. Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation. Cell Metab. 2013; 17(1):49–60. [PubMed: 23312283]

72. Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013; 19(5):576–85. DOI: 10.1038/nm.3145 [PubMed: 23563705]

73. Tang WH, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med. 2013; 368(17):1575–84. [PubMed: 23614584]

74. Wang Z, Tang WH, Buffa JA, Fu X, Britt EB, Koeth RA, et al. Prognostic value of choline and betaine depends on intestinal microbiota-generated metabolite trimethylamine-N-oxide. Eur Heart J. 2014; 35(14):904–10. DOI: 10.1093/eurheartj/ehu002 [PubMed: 24497336]

75. Gregory JC, Buffa JA, Org E, Wang Z, Levison BS, Zhu W, et al. Transmission of atherosclerosis susceptibility with gut microbial transplantation. J Biol Chem. 2015; 290(9):5647–60. DOI: 10.1074/jbc.M114.618249 [PubMed: 25550161]

76. Krueger SK, Williams DE. Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism. Pharmacol Ther. 2005; 106(3):357–87. [PubMed: 15922018]

77. Shih DM, Wang Z, Lee R, Meng Y, Che N, Charugundla S, et al. Flavin containing monooxygenase 3 exerts broad effects on glucose and lipid metabolism and atherosclerosis. J Lipid Res. 2015; 56(1):22–37. DOI: 10.1194/jlr.M051680 [PubMed: 25378658]

78. Warrier M, Shih DM, Burrows AC, Ferguson D, Gromovsky AD, Brown AL, et al. The TMAO-generating enzyme flavin monooxygenase 3 is a central regulator of cholesterol balance. Cell Rep. 2015; 10(3):326–38. DOI: 10.1016/j.celrep.2014.12.036

79. Zhu W, Gregory JC, Org E, Buffa JA, Gupta N, Wang Z, et al. Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk. Cell. 2016; 165(1):111–24. DOI: 10.1016/j.cell.2016.02.011 [PubMed: 26972052]

80. Hartiala J, Bennett BJ, Tang WH, Wang Z, Stewart AF, Roberts R, et al. Comparative genome-wide association studies in mice and humans for trimethylamine N-oxide, a proatherogenic metabolite of choline and L-carnitine. Arterioscler Thromb Vasc Biol. 2014; 34(6):1307–13. DOI: 10.1161/ATVBAHA.114.303252 [PubMed: 24675659]

81. Rhee EP, Ho JE, Chen MH, Shen D, Cheng S, Larson MG, et al. A genome-wide association study of the human metabolome in a community-based cohort. Cell Metab. 2013; 18(1):130–43. DOI: 10.1016/j.cmet.2013.06.013 [PubMed: 23823483]

82. Goodrich JK, Waters JL, Poole AC, Sutter JL, Koren O, Blekhman R, et al. Human genetics shape the gut microbiome. Cell. 2014; 159(4):789–99. DOI: 10.1016/j.cell.2014.09.053 [PubMed: 25417156]

83. Goodrich JK, Davenport ER, Beaumont M, Jackson MA, Knight R, Ober C, et al. Genetic determinants of the gut microbiome in uk twins. Cell Host Microbe. 2016; 19(5):731–43. DOI: 10.1016/j.chom.2016.04.017 [PubMed: 27173935]

84. Wang J, Thingholm LB, Skieceviciene J, Rausch P, Kummen M, Hov JR, et al. Genome-wide association analysis identifies variation in vitamin D receptor and other host factors influencing the gut microbiota. Nat Genet. 2016; 48(11):1396–406. DOI: 10.1038/ng.3695 [PubMed: 27723756]

85. Bonder MJ, Kurilshikov A, Tigchelaar EF, Mujagic Z, Imhann F, Vila AV, et al. The effect of host genetics on the gut microbiome. Nat Genet. 2016; 48(11):1407–12. DOI: 10.1038/ng.3663 [PubMed: 27694959]

86. Turpin W, Espin-Garcia O, Xu W, Silverberg MS, Kevans D, Smith MI, et al. Association of host genome with intestinal microbial composition in a large healthy cohort. Nat Genet. 2016; 48(11): 1413–7. DOI: 10.1038/ng.3693 [PubMed: 27694960]

87•. Org E, Parks BW, Joo JW, Emert B, Schwartzman W, Kang EY, et al. Genetic and environmental control of host-gut microbiota interactions. Genome Res. 2015; 25(10):1558–69. Using a panel of inbred mouse strains, this was the first study to demonstrate that host genetic variation was associated with the abudance of bacterial taxa. DOI: 10.1101/gr.194118.115 [PubMed: 26260972]

88. Roberts LD, Gerszten RE. Toward new biomarkers of cardiometabolic diseases. Cell Metab. 2013; 18(1):43–50. DOI: 10.1016/j.cmet.2013.05.009 [PubMed: 23770128]

89. Civelek M, Lusis AJ. Systems genetics approaches to understand complex traits. Nat Rev Genet. 2014; 15(1):34–48. DOI: 10.1038/nrg3575 [PubMed: 24296534]

90•. Hartiala JA, Tang WH, Wang Z, Crow AL, Stewart AF, Roberts R, et al. Genome-wide association study and targeted metabolomics identifies sex-specific association of CPS1 with coronary artery disease. Nat Commun. 2016; 7:10558. This study implicated glycine metabolism as a female - specific mechanism for CAD by integrating targeted metabolomics and unbiased genomics strategies. doi: 10.1038/ncomms10558 [PubMed: 26822151]

91. Mittelstrass K, Ried JS, Yu Z, Krumsiek J, Gieger C, Prehn C, et al. Discovery of sexual dimorphisms in metabolic and genetic biomarkers. PLoS Genet. 2011; 7(8):e1002215. [PubMed: 21852955]

92. Pare G, Chasman DI, Parker AN, Zee RR, Malarstig A, Seedorf U, et al. Novel associations of CPS1, MUT, NOX4, and DPEP1 with plasma homocysteine in a healthy population: a genome-wide evaluation of 13 974 participants in the Women's Genome Health Study. Circ Cardiovasc Genet. 2009; 2(2):142–50. DOI: 10.1161/CIRCGENETICS.108.829804 [PubMed: 20031578]

93. Lange LA, Croteau-Chonka DC, Marvelle AF, Qin L, Gaulton KJ, Kuzawa CW, et al. Genome-wide association study of homocysteine levels in Filipinos provides evidence for CPS1 in women and a stronger MTHFR effect in young adults. Hum Mol Genet. 2010; 19(10):2050–8. [PubMed: 20154341]

94. Williams SR, Yang Q, Chen F, Liu X, Keene KL, Jacques P, et al. Genome-wide meta-analysis of homocysteine and methionine metabolism identifies five one carbon metabolism loci and a novel association of ALDH1L1 with ischemic stroke. PLoS Genet. 2014; 10(3):e1004214.doi: 10.1371/journal.pgen.1004214 [PubMed: 24651765]

95. Kottgen A, Pattaro C, Boger CA, Fuchsberger C, Olden M, Glazer NL, et al. New loci associated with kidney function and chronic kidney disease. Nat Genet. 2010; 42(5):376–84. [PubMed: 20383146]

96. Choe CU, Atzler D, Wild PS, Carter AM, Boger RH, Ojeda F, et al. Homoarginine levels are regulated by L-arginine:glycine amidinotransferase and affect stroke outcome: results from human and murine studies. Circulation. 2013; 128(13):1451–61. DOI: 10.1161/CIRCULATIONAHA. 112.000580 [PubMed: 24004504]

97. Kleber ME, Seppala I, Pilz S, Hoffmann MM, Tomaschitz A, Oksala N, et al. Genome-wide association study identifies 3 genomic loci significantly associated with serum levels of homoarginine: the AtheroRemo Consortium. Circ Cardiovasc Genet. 2013; 6(5):505–13. DOI: 10.1161/CIRCGENETICS.113.000108 [PubMed: 24047826]

98. Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, et al. Global Lipids Genetics Consortium. Discovery and refinement of loci associated with lipid levels. Nat Genet. 2013; 45(11):1274–83. DOI: 10.1038/ng.2797 [PubMed: 24097068]

99. Danik JS, Pare G, Chasman DI, Zee RY, Kwiatkowski DJ, Parker A, et al. Novel loci, including those related to Crohn disease, psoriasis, and inflammation, identified in a genome-wide association study of fibrinogen in 17 686 women: the Women's Genome Health Study. Circ Cardiovasc Genet. 2009; 2(2):134–41. [PubMed: 20031577]

100. Schemmer P, Zhong Z, Galli U, Wheeler MD, Xiangli L, Bradford BU, et al. Glycine reduces platelet aggregation. Amino Acids. 2013; 44(3):925–31. DOI: 10.1007/s00726-012-1422-8 [PubMed: 23135224]

101. Hasegawa S, Ichiyama T, Sonaka I, Ohsaki A, Okada S, Wakiguchi H, et al. Cysteine, histidine and glycine exhibit anti-inflammatory effects in human coronary arterial endothelial cells. Clin Exp Immunol. 2012; 167(2):269–74. DOI: 10.1111/j.1365-2249.2011.04519.x [PubMed: 22236003]

102. Wheeler M, Stachlewitz RF, Yamashina S, Ikejima K, Morrow AL, Thurman RG. Glycine-gated chloride channels in neutrophils attenuate calcium influx and superoxide production. FASEB J. 2000; 14(3):476–84. [PubMed: 10698962]

103. Bruck R, Wardi J, Aeed H, Avni Y, Shirin H, Avinoach I, et al. Glycine modulates cytokine secretion, inhibits hepatic damage and improves survival in a model of endotoxemia in mice. Liver Int. 2003; 23(4):276–82. [PubMed: 12895268]

104. Spittler A, Reissner CM, Oehler R, Gornikiewicz A, Gruenberger T, Manhart N, et al. Immunomodulatory effects of glycine on LPS-treated monocytes: reduced TNF-alpha production and accelerated IL-10 expression. FASEB J. 1999; 13(3):563–71. [PubMed: 10064624]

105. Ding Y, Svingen GF, Pedersen ER, Gregory JF, Ueland PM, Tell GS, et al. Plasma glycine and risk of acute myocardial infarction in patients with suspected stable angina pectoris. J Am Heart Assoc. 2016; 5(1)doi: 10.1161/JAHA.115.002621

106. Chapman MJ, Stock JK, Ginsberg HN, Forum P. PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era. Curr Opin Lipidol. 2015; 26(6):511–20. DOI: 10.1097/MOL. 0000000000000239 [PubMed: 26780005]

107. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015; 372(16):1500–9. DOI: 10.1056/NEJMoa1500858 [PubMed: 25773607]

108. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015; 372(16):1489–99. DOI: 10.1056/NEJMoa1501031 [PubMed: 25773378]

109. Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJ, et al. Effect of evolocumab on progression of coronary disease in statin-treated patients: The GLAGOV randomized clinical trial. JAMA. 2016; doi: 10.1001/jama.2016.16951

110. Gaudet D, Alexander VJ, Baker BF, Brisson D, Tremblay K, Singleton W, et al. Antisense inhibition of apolipoprotein c-iii in patients with hypertriglyceridemia. N Engl J Med. 2015; 373(5):438–47. DOI: 10.1056/NEJMoa1400283 [PubMed: 26222559]

111. Digenio A, Dunbar RL, Alexander VJ, Hompesch M, Morrow L, Lee RG, et al. Antisense-mediated lowering of plasma apolipoprotein c-iii by volanesorsen improves dyslipidemia and insulin sensitivity in type 2 diabetes. Diabetes Care. 2016; 39(8):1408–15. DOI: 10.2337/dc16-0126 [PubMed: 27271183]

112. https://investor.lilly.com/releasedetail.cfm?releaseid=936130.

113. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007; 357(21):2109–22. DOI: 10.1056/NEJMoa0706628 [PubMed: 17984165]

114. Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE, et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med. 2014; 371(25):2383–93. DOI: 10.1056/NEJMoa1409065 [PubMed: 25404125]

115. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011; 364(2):127–35. DOI: 10.1056/NEJMoa1001689 [PubMed: 21226578]

116. Li XM, Tang WH, Mosior MK, Huang Y, Wu Y, Matter W, et al. Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks. Arterioscler Thromb Vasc Biol. 2013; 33(7):1696–705. DOI: 10.1161/ATVBAHA.113.301373 [PubMed: 23520163]

117. Ridker PM. From C-reactive protein to interleukin-6 to interleukin-1: Moving upstream to identify novel targets for atheroprotection. Circ Res. 2016; 118(1):145–56. DOI: 10.1161/CIRCRESAHA.115.306656 [PubMed: 26837745]

118. Zhang J, Xie F, Yun H, Chen L, Muntner P, Levitan EB, et al. Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis. Ann Rheum Dis. 2016; 75(10):1813–8. DOI: 10.1136/annrheumdis-2015-207870 [PubMed: 26792814]

119. Vrieze A, Van Nood E, Holleman F, Salojarvi J, Kootte RS, Bartelsman JF, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012; 143(4):913–6e7. DOI: 10.1053/j.gastro.2012.06.031 [PubMed: 22728514]

120. Craciun S, Balskus EP. Microbial conversion of choline to trimethylamine requires a glycyl radical enzyme. Proc Natl Acad Sci U S A. 2012; 109(52):21307–12. DOI: 10.1073/pnas.1215689109 [PubMed: 23151509]

121. Sandhu SS, Chase T Jr. Aerobic degradation of choline by Proteus mirabilis: enzymatic requirements and pathway. Can J Microbiol. 1986; 32(9):743–50. [PubMed: 3536045]

122•. Wang Z, Roberts AB, Buffa JA, Levison BS, Zhu W, Org E, et al. Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis. Cell. 2015; 163(7):1585–95. This elegant mouse study is one of the first to demonstrate that pharmacological manipulation of gut bacterial enzymatic processes can be used to treat atherosclerosis. DOI: 10.1016/j.cell.2015.11.055 [PubMed: 26687352]

123. Brook RD, Rajagopalan S, Pope CA 3rd, Brook JR, Bhatnagar A, Diez-Roux AV, et al. Particulate matter air pollution and cardiovascular disease: An update to the scientific statement from the American Heart Association. Circulation. 2010; 121(21):2331–78. DOI: 10.1161/CIR.0b013e3181dbece1 [PubMed: 20458016]

124. Holdt LM, Stahringer A, Sass K, Pichler G, Kulak NA, Wilfert W, et al. Circular non-coding RNA ANRIL modulates ribosomal RNA maturation and atherosclerosis in humans. Nat Commun. 2016; 7:12429.doi: 10.1038/ncomms12429 [PubMed: 27539542]

Figure 1. Genetic mechanisms that promote the development of atherosclerosis
There is strong evidence that common variants are associated with risk of CAD, particularly through pathways related to lipid metabolism, blood pressure, and inflammation. However, these variants collectively still only explain a small fraction of the heritability of CAD. Rare variants have also been identified in the population that affect risk of CAD, mostly through effects on lipids or blood pressure, but evidence that these types of alleles make a substantial contribution the genetic variability in CAD is only moderate. Similarly, emerging data provides evidence for a direct role of intestinal microbes in atherosclerosis and thus far has been shown to involve the effects of gut bacteria-derived metabolites of choline and L-carnitine on lipid and inflammatory pathways. It is also widely hypothesized that gene-gene, gene-sex, and gene-environment interactions contribute to risk of CAD but these are areas that have yet to be explored on a large scale, presumably due, in part, to the challenges posed by the required statistical methodology and imprecise measures of exposure. Positive signs in parentheses indicate strong (+++), moderate (++), or weak (+) evidence for involvement of the indicated genetic mechanism in the pathogenesis of CAD.

Table 1

Loci Identified for CAD through Large-scale Genetic Studies.

Chr	Locus/Nearest gene(s)	Lead SNP	Risk Allele/Other Allele	EAF	OR (95% CI)*	P-value
1	PPAP2B	rs9970807	C/T	0.92	1.13 (1.10 – 1.17)	5.0×10^{-14}
1	PCSK9	rs11206510	T/C	0.85	1.08 (1.05 – 1.11)	2.3×10^{-8}
1	SORT1	rs7528419	A/G	0.79	1.12 (1.10 – 1.15)	2.0×10^{-23}
1	IL6R	rs6689306	A/G	0.45	1.06 (1.04 – 1.08)	2.6×10^{-9}
1	MIA3	rs67180937	G/T	0.66	1.08 (1.06 – 1.11)	1.0×10^{-12}
2	LINC00954	rs16986953	A/G	0.11	1.09 (1.06 – 1.12)	1.5×10^{-8}
2	APOB	rs515135	C/T	0.79	1.07 (1.04 – 1.10)	3.1×10^{-8}
2	ABCG5/ABCG8	chr2:44074126:Del	Del/Ins	0.75	1.06 (1.04 – 1.09)	2.6×10^{-8}
2	VAMP5/8-GGCx	rs7568458	A/T	0.45	1.06 (1.04 – 1.08)	3.6×10^{-10}
2	ZEB2-AC074093.1	rs17678683	G/T	0.09	1.10 (1.07 – 1.14)	3.0×10^{-9}
2	WDR12	chr2:203828796:I	Ins/Del	0.11	1.15 (1.11 – 1.18)	2.2×10^{-18}
3	MRAS	chr3:138099161:I	Ins/Del	0.16	1.08 (1.05 – 1.10)	2.9×10^{-9}
4	EDNRA	rs4593108	C/G	0.80	1.07 (1.05 – 1.10)	8.8×10^{-10}
4	GUCY1A3	rs72689147	G/T	0.82	1.07 (1.05 – 1.10)	6.1×10^{-9}
4	REST-NOA1	rs17087335	T/G	0.21	1.06 (1.04 – 1.09)	4.6×10^{-8}
6	PHACTR1	rs9349379	G/A	0.43	1.14 (1.12 – 1.16)	1.8×10^{-42}
6	KCNK5	rs56336142	T/C	0.81	1.07 (1.04 – 1.09)	1.9×10^{-8}
6	TCF21	rs12202017	A/G	0.70	1.07 (1.05 – 1.09)	2.0×10^{-11}
6	SLC22A3-LPAL2-LPA	rs55730499	T/C	0.06	1.37 (1.31 – 1.44)	5.4×10^{-39}
6	PLG	rs4252185	C/T	0.06	1.34 (1.28 – 1.41)	1.6×10^{-32}
7	NOS3	rs3918226	T/C	0.06	1.14 (1.09 – 1.29)	1.7×10^{-9}
7	HDAC9	rs2107595	A/G	0.20	1.08 (1.05 – 1.10)	8.1×10^{-11}
7	ZC3HC1	rs11556924	C/T	0.69	1.08 (1.05 – 1.10)	5.3×10^{-11}
9	9p21/CDKN2B-CDKN2A	rs2891168	G/A	0.49	1.21 (1.19 – 1.24)	2.3×10^{-98}
9	ABO	rs2519093	T/C	0.19	1.08 (1.06 – 1.11)	1.2×10^{-11}
10	KIAA1462	rs2487928	A/G	0.42	1.06 (1.04 – 1.08)	4.4×10^{-11}
10	CxCL12	rs1870634	G/T	0.64	1.08 (1.06 – 1.10)	5.6×10^{-15}

Chr	Locus/Nearest gene(s)	Lead SNP	Risk Allele/Other Allele	EAF	OR (95% CI)[*]	P-value
10	LIPA	rs1412444	T/C	0.37	1.07 (1.05 – 1.09)	5.2×10^{-12}
10	CYP17A1-CNNM2-NT5C2	rs11191416	T/G	0.87	1.08 (1.05 – 1.11)	4.7×10^{-9}
11	PDGFD	rs2128739	A/C	0.32	1.07 (1.05 – 1.09)	7.1×10^{-11}
11	SWAP70	rs10840293	A/G	0.55	1.06 (1.04 – 1.08)	1.3×10^{-8}
12	ATP2B1	rs2681472	G/A	0.20	1.08 (1.05 – 1.10)	6.2×10^{-11}
12	SH2B3	rs3184504	T/C	0.42	1.07 (1.04 – 1.09)	1.0×10^{-9}
12	KSR2	rs11830157	G/T	0.36	1.12 (1.08 – 1.16)[**]	2.1×10^{-9}
13	COL4A1/A2	rs4773144	A/G	0.26	1.07 (1.05 – 1.09)	1.8×10^{-10}
14	HHIPL1	rs10139550	G/C	0.42	1.06 (1.04 – 1.08)	1.4×10^{-8}
15	ADAMTS7	rs4468572	C/T	0.59	1.08 (1.06 – 1.10)	4.4×10^{-16}
15	SMAD3	rs56062135	C/T	0.79	1.07 (1.05 – 1.10)	4.5×10^{-9}
15	MFGE8-ABHD2	rs8042271	G/A	0.90	1.10 (1.06 –1.14)	3.7×10^{-8}
17	BCAS3	rs7212798	C/T	0.15	1.08 (1.05 –1.11)	1.9×10^{-8}
18	PMAIP1-MC4R	rs663129	A/G	0.26	1.06 (1.04–1.08)	3.20×10^{-8}
19	LDLR	rs56289821	G/A	0.90	1.14 (1.11 – 1.18)	4.4×10^{-15}
19	APOE	rs4420638	G/A	0.17	1.10 (1.07 – 1.13)	7.1×10^{-11}
19	ZNF507-LOC400684	rs12976411	T/A	0.09	0.67 (0.60 – 0.74)[**]	3.2×10^{-8}
21	KCNE2	rs28451064	A/G	0.12	1.14 (1.10 – 1.17)	1.3×10^{-15}
22	POM121L9P-ADORA2A	rs180803	G/T	0.97	1.20 (1.13 – 1.27)	1.2×10^{-10}

Only loci exceeding the genome-wide threshold for significance (p=5.0×10^{-8}) from the meta-analysis by CARDIoGRAMplusC4D Consortium [7••] are shown.

[*] All ORs refer to allele that increases risk of CAD except for the ZNF507-LOC400684 locus on chromosome 19.

[**] Derived from an analysis assuming recessive inheritance.

Table 2

Genes in Which Rare Variants Are Associated with Risk of CAD.

Discovery Approach	Gene	Type of Mutation	Effect on CAD Risk	Biological Mechanism(s)	Ref.
Family-based	*GUCY1A3*	Loss-of-function	Increase	Decreased nitric oxide signaling, increased blood pressure and thrombus formation	[39]
	CCT7	Loss-of-function	Increase	Decreased nitric oxide signaling and increased thrombus formation	[39]
Targeted sequencing	*PCSK9*	Loss-of-function	Decrease	Lower LDL levels	[40]
	APOC3	Loss-of-function	Decrease	Lower triglyceride levels	[42]
	ANGPTL4	Loss-of-function	Decrease	Lower triglyceride levels	[43]
	SCARB1	Loss-of-function	Increase	Higher HDL levels	[44•]
Exome sequencing	*APOC3*	Loss-of-function	Decrease	Lower triglyceride levels	[45]
	NPC1L1	Loss-of-function	Decrease	Decreased intestinal cholesterol absorption and lower LDL levels	[46]
	APOA5	Loss-of-function	Increase	Higher triglyceride levels	[47]
	LDLR	Loss-of-function	Increase	Higher LDL levels	[47]
Exome chip	*LPA*	Gain-of-function	Increase	Higher Lp(a) levels	[50]
	PCSK9	Loss-of-function	Decrease	Lower LDL levels	[50]
	ANGPTL4	Loss-of-function	Decrease	Lower triglyceride levels	[50]
	LPL	Gain-of-function	Decrease	Lower triglyceride levels	[50]
	LPL	Loss-of-function	Increase	Higher triglyceride levels	[50]
	SVEP1	Unknown	Increase	Increased blood pressure and possibly other unknown pathways	[50]
Whole-genome sequencing	*ASGR1*	Loss-of-function	Decrease	Glycoprotein homeostasis and lower non-HDL levels	[48]